# Tallac Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tallac-therapeutics

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.tallactherapeutics.com
- Total disclosed funding: $62M
- Latest round: Series A (Dec 1, 2020)
- Investors on record: 5

## About

Based in the US, Tallac Therapeutics, Inc. is dedicated to developing innovative antibody drug conjugates (ADCs) that harness both innate and adaptive immunity to fight cancer.Tallac Therapeutics, Inc. was founded in 2018 in Burlingame, US. The company specializes in creating advanced antibody drug conjugates (ADCs) for oncology treatment. Hong Wan, the founder and current CEO, has previously established other ventures. In August 2023, Tallac raised USD 15 mn in VENTURE DEBT funding from Horizon Technology Finance Corporation, contributing to a total amount raised of USD 62 mn and indicating a strong interest from investors in its pipeline.Tallac Therapeutics, Inc. focuses on the development of antibody drug conjugates (ADCs) aimed at combating cancer. Their innovative pipeline includes oligonucleotide-based ADC candidates, particularly Toll-like Receptor Agonist Antibody Conjugates (TRAAC). These therapeutic agents are engineered to deliver potent Toll-like receptor (TLR9) agonists, specifically T-CpG, which activate the immune response in the tumor microenvironment. This technology enables precise conjugation of therapeutic oligonucleotide payloads, such as CpG oligonucleotides, antisense oligonucleotides, and siRNA, moving beyond traditional toxin payloads. Tallac primarily targets markets in North America and Europe, where there is a significant demand for advanced cancer therapies.Tallac Therapeutics operates through a partnership-based revenue model, focusing on collaborations with research institutions, healthcare organizations, and pharmaceutical companies involved in cancer treatment. The company's financial structure includes agreements for the development and commercialization of its TRAAC technology and related ADC products. Revenue generation arises from milestone payments, research funding, and product sales once therapies are approved. The leading program, TAC-001, currently in clinical trials, is indicative of the type of product that would typically involve such financial arrangements.Following the USD 15 mn raised in VENTURE DEBT funding in August 2023, Tallac Therapeutics plans to utilize these funds to further develop its innovative therapies, including the upcoming products in its pipeline. The company aims to expand its presence in North America and Europe, focusing on regions with high demand for cancer therapies. Upcoming product launches are anticipated, although specific release dates have not been disclosed. This funding will support the necessary research and development efforts to bring their ADC technology to market, enhancing their operational capabilities.

## Funding rounds

- Series A, Dec 1, 2020, $62M — VenBio, Lightstone Ventures, MPC, Morningside, MRL Ventures Fund

## Investors

- VenBio (https://capitalatlas.ai/funds/venbio) — Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A
- MPC — Series A
- Morningside (https://capitalatlas.ai/funds/morningside) — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A